

Brilliant Violet 421™ anti-mouse CD11c Antibody

Catalog# / Size	117329 / 125 µL 117343 / 50 µg 117330 / 500 µL
Clone	N418
Regulatory Status	RUO
Other Names	αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype	Armenian Hamster IgG
Description	CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Armenian Hamster
Immunogen	Mouse spleen dendritic cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested IHC - Verified
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser	Violet Laser (405 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunoprecipitation ³ , immunohistochemical staining of acetone-fixed frozen sections ³ , immunofluorescence microscopy ⁵ .

⁹ (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections¹⁰), and spatial biology (IBEX)^{22,23}.

Application References

1. Granucci F, *et al.* 1997. *J. Immunol.* 159:1794.
2. Stokes RW, *et al.* 1998. *J. Immunol.* 160:5514.
3. Metlay JP, *et al.* 1990. *J. Exp. Med.* 171:1753. (IHC, IP)
4. Ma XT, *et al.* 2006. *Cancer Research* 66:1169.
5. Chin RK, *et al.* 2006. *J. Immunol.* 177:290. (IF)
6. Cervantes-Barragan L, *et al.* 2007. *Blood* 109:1131. (FC) [PubMed](#)
7. Turnquist HR, *et al.* 2007. *J. Immunol.* 178:7018. (FC) [PubMed](#)
8. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
9. You Y, *et al.* 2009. *J. Immunol.* 182:7343. (IF) [PubMed](#)
10. Roland CL, *et al.* 2009. *Mol. Cancer Res.* 8:1761. (IHC, FC) [PubMed](#)
11. Wikstrom M, *et al.* 2006. *J. Immunol.* 177:913. [PubMed](#)
12. Pericolini E, *et al.* 2008. *J. Leukocyte Biol.* 83:1286. [PubMed](#)
13. Randall LM, *et al.* 2008. *Infect. Immun.* 76:3312. [PubMed](#)
14. Fahlen-Yrild L, *et al.* 2009. *J. Immunol.* 183:5032. [PubMed](#)
15. Osterholzer JJ, *et al.* 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
17. Eisenach PA, *et al.* 2010. *J Cell Sci.* 123:4182. [PubMed](#)
18. Leppin K, *et al.* 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
19. Sakai F, *et al.* 2014. *PLoS One.* 9:105370. [PubMed](#)
20. Gibbins JD, *et al.* 2014. *Blood.* 124:2953. [PubMed](#)
21. White CE, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)
22. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
23. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
24. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Liu J, *et al.* 2019. *Immunity.* 50:600. [PubMed](#)
2. Kim EH, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
3. Frisbee AL, *et al.* 2019. *Nat Commun.* 10:2712. [PubMed](#)
4. Romain Bouziat *et al.* 2018. *Cell host & microbe.* 24(5):677-688. [PubMed](#)
5. Szulc-D&acedil;browska L, *et al.* 2017. *PLoS One.* 12(6):e0179166. [PubMed](#)
6. Radahl I, *et al.* 2021. *STAR Protoc.* 2:100842. [PubMed](#)
7. Ortiz G, *et al.* 2020. *Front Immunol.* 11:1713. [PubMed](#)
8. Evans H, *et al.* 2015. *J Immunol.* 195: 2973 - 2984. [PubMed](#)
9. Uzhachenko RV, *et al.* 2021. *Cell Reports.* 35(1):108944. [PubMed](#)
10. Saleh MM, *et al.* 2019. *Cell Host Microbe.* 25:756. [PubMed](#)
11. Baptista AP *et al.* 2019. *Immunity.* 50(5):1188-1201. [PubMed](#)
12. Kim CJ, *et al.* 2018. *Immunity.* 49:1034. [PubMed](#)
13. Park S, *et al.* 2021. *Front Immunol.* 11:620166. [PubMed](#)
14. Adachi Y, *et al.* 2022. *Nat Commun.* 13:5117. [PubMed](#)
15. Tyagi AM *et al.* 2018. *Immunity.* 49(6):1116-1131. [PubMed](#)
16. Chen J, *et al.* 2022. *J Nanobiotechnology.* 20:283. [PubMed](#)
17. Nagatake T, *et al.* 2022. *Mucosal Immunol.* 15:289. [PubMed](#)
18. Saito S, *et al.* 2020. *Nutrients.* 12:. [PubMed](#)
19. Molina-Sanchez P, *et al.* 2020. *Gastroenterology.* 2203:159. [PubMed](#)
20. Nguyen SL, *et al.* 2021. *Sci Rep.* 11:4217. [PubMed](#)
21. Jenkins RW, *et al.* 2018. *Cancer Discov.* 8:196. [PubMed](#)
22. Jassinskaja M, *et al.* 2021. *Cell Reports.* 34(12):108894. [PubMed](#)
23. Zhang X, *et al.* 2021. *Front Immunol.* 12:680068. [PubMed](#)
24. James BR, *et al.* 2014. *Cancer Immunol Immunother.* 63:1213-1227. [PubMed](#)
25. Smith AS, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
26. Gao H, *et al.* 2021. *Cells.* 10:. [PubMed](#)
27. Zheng J, *et al.* 2020. *bioRxiv.* . [PubMed](#)
28. Hossain DMS, *et al.* 2018. *J Clin Invest.* 128:644. [PubMed](#)
29. Synn CB, *et al.* 2022. *Clin Transl Immunology.* 11:e1364. [PubMed](#)
30. Grigoryan L, *et al.* 2022. *NPJ Vaccines.* 7:55. [PubMed](#)
31. Ringel AE, *et al.* 2020. *Cell.* 183(7):1848-1866.e26. [PubMed](#)
32. Bayik D, *et al.* 2020. *Cancer Discov.* 1.256944444. [PubMed](#)
33. Jürchott K, *et al.* 2016. *PLoS One.* 11: 0150812. [PubMed](#)
34. O'Connor T, *et al.* 2020. *Cancer Cell.* 36(3):250-267. [PubMed](#)
35. Bradley KC, *et al.* 2019. *Cell Rep.* 28:245. [PubMed](#)
36. Kumar MP, *et al.* 2018. *Cell Rep.* 25:1458. [PubMed](#)
37. Lee DH, *et al.* 2019. *PLoS One.* 14:e0215727. [PubMed](#)
38. Chen G, *et al.* 2021. *Sci Adv.* 7:eabg5686. [PubMed](#)
39. Kim SH, *et al.* 2021. *Cell Reports.* 35(2):108995. [PubMed](#)
40. Zhang J, *et al.* 2018. *Sci Rep.* 8:2373. [PubMed](#)
41. Matundan H, *et al.* 2019. *J Virol.* 93. [PubMed](#)
42. Matundan HH, *et al.* 2021. *J Virol.* 95:e0103621. [PubMed](#)
43. Zheng J, *et al.* 2020. *Nature.* . [PubMed](#)
44. Kälin S *et al.* 2017. *Cell metabolism.* 26(3):475-492. [PubMed](#)
45. Otvos B, *et al.* 2021. *Clin Cancer Res.* 27:2038. [PubMed](#)
46. Jaggi U, *et al.* 2021. *PLoS Pathog.* 17:e1009999. [PubMed](#)
47. Giampazolias E, *et al.* 2021. *Cell.* . [PubMed](#)
48. Gomez S, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
49. Nagatake T, *et al.* 2018. *J Allergy Clin Immunol.* 142:470. [PubMed](#)
50. Xu G, *et al.* 2022. *Front Pharmacol.* 13:896601. [PubMed](#)

51. Huang L, *et al.* 2021. *Frontiers in Cellular and Infection Microbiology*. 10:606340. [PubMed](#)
52. Wang S, *et al.* 2022. *J Inflamm Res*. 14:7107. [PubMed](#)
53. Sanders K, *et al.* 2015. *Cancer Immunol Res*. 3: 891-901. [PubMed](#)
54. Xu W, *et al.* 2021. *Immunity*. 54(3):526-541.e7. [PubMed](#)
55. Serr I, *et al.* 2016. *Proc Natl Acad Sci U S A*. 113: E6659 - E6668. [PubMed](#)
56. Seenappa LM, *et al.* 2022. *NPJ Vaccines*. 7:128. [PubMed](#)
57. Cardoso M, *et al.* 2015. *Infect Immun*. 83: 3534-3544. [PubMed](#)
58. Serr I, *et al.* 2016. *Nat Commun*. 7:10991. [PubMed](#)
59. Chmielewski M and Abken H 2017. *Cell Rep.*. 10.1016/j.celrep.2017.11.063. [PubMed](#)
60. Lytle NK *et al.* 2019. *Cell*. 177(3):572-586. [PubMed](#)
61. Tanegashima K *et al.* 2017. *EBioMedicine*. 24:247-256. [PubMed](#)
62. Boguslawski KM, *et al.* 2020. *Sci Adv*. 6:eaax7515. [PubMed](#)
63. Wang Y, *et al.* 2020. *Vaccines (Basel)*. 8:. [PubMed](#)
64. Lee A, *et al.* 2022. *Nat Commun*. 13:549. [PubMed](#)
65. Spiljar M, *et al.* 2021. *Cell Metab*. 33:2231. [PubMed](#)
66. Avgustinova A, *et al.* 2021. *Cell Stem Cell*. [PubMed](#)
67. Cardoso F, *et al.* 2015. *PLoS One*. 10: 0131904. [PubMed](#)
68. Song W, *et al.* 2022. *Immunity*. 55:290. [PubMed](#)

RRID AB_10897814 (BioLegend Cat. No. 117329)
 AB_2563099 (BioLegend Cat. No. 117343)
 AB_11219593 (BioLegend Cat. No. 117330)

Antigen Details

Structure	Integrin α -chain, associates with integrin β_2 (CD18), 150 kD
Distribution	Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells
Function	Cellular adhesion
Ligand/Receptor	iC3b, fibrinogen
Cell Type	Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen Facts Book</i> Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Lopez-Rodriguez C, <i>et al.</i> 1996. <i>J. Immunol</i> . 156:3780.
Gene ID	16411




Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD11c, Biotin anti-mouse CD11c, FITC anti-mouse CD11c, PE anti-mouse CD11c, Purified anti-mouse CD11c, Alexa Fluor® 488 anti-mouse CD11c, Alexa Fluor® 647 anti-mouse CD11c, PE/Cyanine5 anti-mouse CD11c, PE/Cyanine7 anti-mouse CD11c, Brilliant Violet 605™ anti-mouse CD11c, Alexa Fluor® 700 anti-mouse CD11c, Pacific Blue™ anti-mouse CD11c, APC/Cyanine7 anti-mouse CD11c, PerCP/Cyanine5.5 anti-mouse CD11c, PerCP anti-mouse CD11c, Brilliant Violet 421™ anti-mouse CD11c, Brilliant Violet 570™ anti-mouse CD11c, Brilliant Violet 785™ anti-mouse CD11c, Brilliant Violet 510™ anti-mouse CD11c, Brilliant Violet 650™ anti-mouse CD11c, Purified anti-mouse CD11c (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD11c, PE/Dazzle™ 594 anti-mouse CD11c, Brilliant Violet 711™ anti-mouse CD11c, APC/Fire™ 750 anti-mouse CD11c, TotalSeq™-A0106 anti-mouse CD11c, Brilliant Violet 750™ anti-mouse CD11c, TotalSeq™-B0106 anti-mouse CD11c, TotalSeq™-C0106 anti-mouse CD11c, KIRAVIA Blue 520™ anti-mouse CD11c, Spark Blue™ 550 anti-mouse CD11c, Spark NIR™ 685 anti-mouse CD11c, Spark UV™ 387 anti-mouse CD11c, Spark Red™ 718 anti-mouse CD11c

Product Data



C57BL/6 mouse splenocytes were stained with mouse I-A/I-E FITC and CD11c (clone N418) Brilliant Violet 421™ (top) or Armenian hamster IgG Brilliant Violet 421™ isotype control (bottom).

C57BL/6 mouse lymph nodes, fixed O/N in PLP, blocked with 10% rat serum, and stained with CD11c- BV421™ (red), B220-Alexa Fluor® 647 (blue), and I-A/I-E-FITC (green) in 1% BSA and 0.1% Tween-20 in PBS. Images were acquired with an automated widefield microscope (Nikon Eclipse Ti) and a CCD camera (QImaging Retiga 2000R). Emitted light was collected through 440/40, 525/50, and 700/75 nm bandpass filters. Images provided by Ann Haberman and Christine Podolski, Yale University.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587